Insider Activity Snapshot: NVIDIA Sales Dominate as Executives Across Tech and Biotech Trade Stock

Here is a detailed review of the most consequential insider trading disclosures filed for US-traded companies as reported on Wednesday, September 9, 2026. The activity spans small- and mid-cap issuers as well as large-cap technology names, and includes purchases executed directly and indirectly, exchanges to satisfy receivables, and sales carried out under pre-existing trading plans.

Alumis Inc. recorded substantial insider activity in early September. Director Srinivas Akkaraju, acting through investment vehicles, recorded net activity that included purchases exceeding $10.7 million and sales in excess of $1 million. Specific filings show that on September 4, 2026, Mr. Akkaraju indirectly acquired 440,140 shares of Alumis common stock at prices ranging from $11.02 to $11.60 per share, for a total consideration of $4,917,684. At the time of the filings ALMS was trading at $9.80 and is down materially from its 52-week high of $31.35. Public data noted in the filings indicate the share price has fallen 65% over the past six months despite a 128% gain over the last year. InvestingPro analysis cited in the disclosure characterizes the stock as appearing overvalued at current levels.

Greenwave Technology Solutions, Inc. disclosed a material non‑cash acquisition by Chief Executive Officer and 10% owner Danny Meeks. On August 27, 2026, Mr. Meeks, through DWM Properties LLC - an entity he wholly owns - acquired 2,152,853 shares of the company's common stock. The transaction was valued at $8,000,001 and executed at a per-share price of $3.716. According to the filing, DWM Properties LLC received the shares in exchange for the satisfaction of an outstanding note and other receivables owed to DWM and Mr. Meeks, under an Exchange Agreement dated August 24, 2026, between Greenwave Technology Solutions and DWM Properties LLC.

Inhibrx Biosciences, Inc. reported a director purchase on September 8, 2026. Director Jon Faiz Kayyem acquired 5,000 shares of common stock for a total of $567,580. The individual trade prices ranged from $113.30 to $113.55 per share, producing a weighted-average purchase price of $113.516. At the time of reporting the stock was trading at $114.34. Filings highlight that the share price is down roughly 9% over the past week while delivering a 286% return over the past year. InvestingPro analysis referenced in the disclosure indicates that INBX appears overvalued relative to its Fair Value and mentions 13 additional tips available to investors evaluating the name.

Cytosorbents Corporation also recorded insider buying. Chief Executive Officer and director Phillip P. Chan purchased 200,000 shares of the company’s common stock in an open market transaction on September 4, 2026. The trades were executed at prices ranging from $0.3470 to $0.3599 per share, with a weighted-average price of $0.35, resulting in a total transaction value of $70,000. The filing notes that the stock has declined 66% over the past year and is trading at $6.33. InvestingPro analysis cited alongside the filing characterizes CTSO as appearing undervalued relative to its Fair Value, a factor the filing implies may have influenced the CEO’s decision to add to his position.

NVIDIA Corp. reported the most sizable insider disposal by dollar value in early September. Director Mark A. Stevens sold common stock aggregating approximately $235.6 million across transactions on September 3 and September 4, 2026. The reported price range for these sales spanned $227.6954 to $234.0043 per share. On September 3, Mr. Stevens sold 198,707 shares at a weighted-average price of $227.6954, with individual trade prices ranging from $227.25 to $228.2493. Later that same day he sold an additional 1,293 shares at a weighted-average price of $228.2703, with prices between $228.25 and $228.2881. A third reported transaction that day involved 200,000 shares sold at a weighted-average price of $229.8705, with execution prices ranging from $229.545 to $230.16. At the time of the filings NVIDIA was trading near its 52-week high of $236.54 and was recorded at $225.73. The filing notes that the semiconductor company maintains a market capitalization of $5.45 trillion.

Dell Technologies Inc. also disclosed a large block sale. Significant shareholder and director Silver Lake Partners IV, L.P., together with director Egon Durban, reported the sale of Dell Class C Common Stock totaling about $48.1 million on September 4, 2026. The transactions encompassed the disposition of 93,234 shares of Class C Common Stock. For the shares indirectly held by Silver Lake Partners IV, L.P., weighted average prices spanned $515.53 to $529.16 per share; for shares directly held by Mr. Durban, weighted average prices ranged from $518.21 to $525.22 per share. Across the reported transactions individual sale prices ranged from $515.00 to $529.66. The filing puts Dell’s trading level at $535.25, near a 52-week high of $563, following a reported 336% gain over the past year. InvestingPro data cited in the disclosure indicates Dell appears overvalued versus its Fair Value estimate, while noting a PEG ratio of 0.2.

BELITE BIO, INC recorded multiple insider sales in early September. Chief Executive Officer and director Lin Yu-Hsin sold a total of 90,835 American depositary shares across transactions on September 4 and September 8, 2026, generating proceeds of approximately $19.08 million. The ADSs were sold at prices between $180.00 and $198.37 per share, trading levels that sit near the company’s 52-week high of $200. The filing reiterates that each ADS represents one ordinary share of BELITE BIO and includes InvestingPro’s assessment that the stock remains undervalued at current levels, along with a note that 15 additional ProTips are available to subscribers.

Also for BELITE BIO, Chief Financial Officer and Director Chuang Hao-Yuan sold 62,395 ADSs on September 4 and September 8, 2026, for approximately $12,803,527. The per-ADS prices reported ranged from $180.1597 to $198.0454. The filing specifies that these transactions were executed pursuant to a Rule 10b5-1 trading plan Mr. Chuang adopted on December 22, 2025. Post-sale holdings disclosed show Mr. Chuang directly holds 26,038 ADSs. The filing reiterates the share-level context: the ADSs trade near a 52-week high of $200 and the company has delivered a 176% return over the past year. InvestingPro analysis included in the disclosure states BLTE presently appears undervalued relative to its Fair Value, while also noting the shares have traded in overbought territory.

Workday, Inc. reported the disposition of Class A Common Stock by Director and 10% owner David A. Duffield. The filing shows sales on September 4, 2026, totaling approximately $17,954,367. The transactions were carried out under a Rule 10b5-1 trading plan previously adopted by the David A. Duffield Trust on December 2, 2025, and involved 90,815 shares sold in multiple trades at prices ranging from $195.42 to $205.05 per share. The filing notes Workday’s share performance has been resilient, with a 26% gain over the past six months, and that the company has a market value of $44.9 billion. InvestingPro analysis appended to the filing characterizes WDAY as appearing undervalued relative to its Fair Value and points to available Pro Research Reports.

These Form 4 filings reflect a mix of strategic buying, balance-sheet-driven exchanges and planned disposals. Some purchases were open market additions, while others were non-cash acquisitions undertaken to satisfy outstanding notes or receivables. Several sales were executed under Rule 10b5-1 plans, a mechanism that can allow insiders to systematically sell stock according to pre-set arrangements.

Valuation commentary from InvestingPro was referenced repeatedly in the filings. That analysis described certain names as appearing overvalued versus their Fair Value estimates - alumis and Inhibrx were cited in that category - while other issuers, including Cytosorbents, BELITE BIO and Workday, were characterized as appearing undervalued by the same source. Dell was singled out as apparently overvalued relative to its Fair Value despite an attractive PEG ratio noted in the disclosure.

Investors monitoring insider activity often weigh the nature and timing of transactions - distinguishing between cash purchases, non-cash exchanges and sales carried out pursuant to trading plans - before drawing conclusions about management sentiment. Filings do not assign a single interpretation to observed trades: insiders sell for a range of personal and corporate reasons, and purchases can reflect opportunistic accumulation or other strategic motives.

• Insider buying was concentrated at smaller-cap issuers such as Alumis, Greenwave, Inhibrx and Cytosorbents, with purchases ranging from open market acquisitions to exchanges that satisfied receivables.
• Large-dollar insider sales were reported at major technology and growth names - NVIDIA and Dell lead the list - with sales executed near recent highs and, in some cases, via Rule 10b5-1 plans.
• Third-party valuation notes included in the filings paint a mixed picture: certain tickers were described as appearing overvalued relative to Fair Value, while others were flagged as undervalued, underscoring divergent views on relative price and fundamentals.

• Insider sales do not necessarily indicate deteriorating corporate fundamentals - they may reflect planned liquidity needs or systematic dispositions under trading plans. This ambiguity affects interpretation for sectors such as technology and enterprise software, where sizeable insiders sales were disclosed.
• Valuation characterizations cited from InvestingPro introduce model-driven judgments that may conflict with market pricing; reliance on those assessments can create uncertainty for investors in biotech and small-cap names where valuations were described as over- or undervalued.
• Non-cash transactions, such as exchanges to satisfy notes, change insider ownership without immediate cash flow and may complicate straightforward readings of conviction-based buying, particularly in smaller-cap issuers where such trades were disclosed.

Monitoring insider filings remains one input among many for investors evaluating stock positions. Filings from early September 2026 illustrate how executives and directors use a variety of mechanisms to buy and sell equity - market purchases, entity exchanges and pre-arranged plans - and how outside valuation commentary is frequently attached to these disclosures. Investors looking for a fuller picture should consider these filings alongside fundamental and technical indicators.

For those tracking these developments, primary source filings and the appended valuation notes provide the factual record of ownership changes and the context pushed into the public domain by third-party analysis.